Xintela is a startup based in Sweden, most recent round Series A, 2 tracked investors.
Based in Sweden, Xintela is a startup founded in 2007. Its most recent tracked round is Series A. Brouky records 2 investors associated with the company.
Xintela is a clinical-stage biopharma company developing stem cell therapies for conditions like osteoarthritis and cancer treatments targeting aggressive tumors. Its proprietary technology uses the stem cell marker integrin α10β1 to select and quality-assure stem cells in the product XSTEM®.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.